A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia

Clicks: 343
ID: 118063
2001
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
In a prospective, multicenter, double-blind, randomized clinical trial, we compared the efficacy of piperacillin-tazobactam (4.5 g 3 times daily intravenously) plus placebo versus piperacillin-tazobactam plus amikacin (7.5 mg/kg twice daily intravenously) for the treatment of 760 febrile, adult pati …
Reference Key
a2001clinicala Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Del Favero A;Menichetti F;Martino P;Bucaneve G;Micozzi A;Gentile G;Furno P;Russo D;D'Antonio D;Ricci P;Martino B;Mandelli F; ;;
Journal Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Year 2001
DOI
DOI not found
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.